Investigational New Drugs

, Volume 27, Issue 2, pp 173–178 | Cite as

Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

  • Noor Al-DasooqiEmail author
  • Joanne M. Bowen
  • Rachel J. Gibson
  • Thomas Sullivan
  • Jude Lees
  • Dorothy M. Keefe


Purpose: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients. Methods: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002–2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. Results: Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (≥60 years) and those with metastatic disease experienced the highest frequency of toxicity. Conclusion: Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancer patients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.


HER2-overexpressing breast cancer Targeted therapy Trastuzumab Gastrointestinal tract Toxicity 



Noor Al-Dasooqi was supported by an Honours scholarship from the Royal Adelaide Hospital; Dr. Rachel J Gibson was supported by a Research Fellowship from the Cancer Council South Australia; Dr. Joanne M Bowen was supported by a Research Fellowship from the Royal Adelaide Hospital; Professor Dorothy M. Keefe is the Cancer Council SA Chair of Cancer Medicine.


  1. 1.
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16:1569–1583 doi: 10.1093/annonc/mdi326 PubMedCrossRefGoogle Scholar
  2. 2.
    Keefe DMK, Gibson RJ (2007) Mucosal injury from targeted anticancer therapy. Support Care Cancer 15:483–490 doi: 10.1007/s00520-006-0181-z PubMedCrossRefGoogle Scholar
  3. 3.
    Simonds HM, Miles D (2007) Adjunctive treatment of breast cancer: impact of monoclonal antibody therapy directed at the HER2 receptor. Expert Opin Biol Ther 7:487–491 doi: 10.1517/14712598.7.4.487 PubMedCrossRefGoogle Scholar
  4. 4.
    Cobleigh MA, Vogel CL, Tripathy D, Robert NJ et al (1999) Multinational study of the efficacy and safety of the humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressinf metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMedGoogle Scholar
  5. 5.
    Nagy P, Jenei A, Damjanovich S, Jovin TM, Szollosi J (1999) Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 5:255–271 doi: 10.1053/paor.1999.0255 PubMedCrossRefGoogle Scholar
  6. 6.
    Baselga J, Albanell J, Molina MA, Arribas J (2001) Mechanism of action of Trastuzumab and scientific update. Semin Oncol 28:4–11 doi: 10.1016/S0093-7754(01)90276-3 PubMedCrossRefGoogle Scholar
  7. 7.
    Baselga J (2001) Clinical trials of Herceptin (Trastuzumab). Eur J Cancer 37:S18–S24 doi: 10.1016/S0959-8049(00)00404-4 PubMedCrossRefGoogle Scholar
  8. 8.
    Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of Trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739–749PubMedCrossRefGoogle Scholar
  9. 9.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjunctive chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684 doi: 10.1056/NEJMoa052122 PubMedCrossRefGoogle Scholar
  10. 10.
    Plosker GL, Keam SJ (2006) Trastuzumab: a review of its use in the management of HER2-positive metastatic and early stage breast cancer. Drugs 66:449–475 doi: 10.2165/00003495-200666040-00005 PubMedCrossRefGoogle Scholar
  11. 11.
    Yeon CH, Pegram MD (2005) Anti-erbB-2 antibody Trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23:391–409 doi: 10.1007/s10637-005-2899-8 PubMedCrossRefGoogle Scholar
  12. 12.
    Badache A, Goncalves A (2006) The ErbB2 signalling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 11:13–25 doi: 10.1007/s10911-006-9009-1 PubMedCrossRefGoogle Scholar
  13. 13.
    Xu H, Yingjie Y, Marciniak D, Rishi A, Sarkar F, Kucuk O et al (2005) Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 4:435–442PubMedGoogle Scholar
  14. 14.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B (2005) Trastuzumab after adjunctive chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672 doi: 10.1056/NEJMoa052306 PubMedCrossRefGoogle Scholar
  15. 15.
    Gibson RJ, Bowen JM, Cummins A, Keefe DMK (2005) Relationship between dose of methotrexate, apoptosis, p53/p21 Expression and intestinal crypt proliferation in the rat. Clin Exp Med 4:188–195 doi: 10.1007/s10238-004-0055-y PubMedCrossRefGoogle Scholar
  16. 16.
    Yeoh A, Bowen JM, Gibson RJ, Keefe D (2005) Nuclear Factor κB (NFκB) and Cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63:1295–1303 doi: 10.1016/j.ijrobp.2005.04.041 PubMedCrossRefGoogle Scholar
  17. 17.
    Sonis ST, Elting L, Keefe D, Peterson D, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer 100:1995–2025 doi: 10.1002/cncr.20162 PubMedCrossRefGoogle Scholar
  18. 18.
    Roche Pharmaceuticals (2006) Herceptin TGA approved product information sheet. Roche Pharmaceuticals, Nutley, NJGoogle Scholar
  19. 19.
    Carraway KL, Ramsauer VP, Haq B, Carraway CA (2003) Cell signalling through membrane mucins. Bioessays 25:66–71 doi: 10.1002/bies.10201 PubMedCrossRefGoogle Scholar
  20. 20.
    Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J et al (2005) Expression, location and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol 203:44–53 doi: 10.1002/jcp.20200 PubMedCrossRefGoogle Scholar
  21. 21.
    Rose MC (1992) Mucins: structure, function and role in pulmonary diseases. Am J Physiol 263:L413–L429PubMedGoogle Scholar
  22. 22.
    Carraway KL, Perez A, Idris N, Jepson S, Arango M, Komatsu M et al (2002) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 71:149–185 doi: 10.1016/S0079-6603(02)71043-X PubMedCrossRefGoogle Scholar
  23. 23.
    Crown JP, Burris HA, Boyle F, Jones S, Koehler M, Newstat BO et al (2008). Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat doi: 10.1007/s10549-007-9860-9
  24. 24.
    Tonato M, Clark-Snow RA, Osoba D, Del Favero A, Ballatori A, Borjeson S (2005) Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13:109–111 doi: 10.1007/s00520-004-0703-5 PubMedCrossRefGoogle Scholar
  25. 25.
    Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) J Clin Oncol 24:1–16 doi: 10.1200/JCO.2006.06.9591 CrossRefGoogle Scholar
  26. 26.
    National Comprehensive Cancer Network (2008) Clinical practice guidelines in clinical oncology. National Comprehensive Cancer Network, Jenkintown, PAGoogle Scholar
  27. 27.
    Warren CM, Landgraf R (2006) Signaling through ErbB receptors: multiple layers of diversity and control. Cell Signal 18:923–933 doi: 10.1016/j.cellsig.2005.12.007 PubMedCrossRefGoogle Scholar
  28. 28.
    Crone SA, Negro A, Trumpp A, Giovannini M, Lee KF (2003) Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron 37:29–40 doi: 10.1016/S0896-6273(02)01128-5 PubMedCrossRefGoogle Scholar
  29. 29.
    Kataoka A, Ishida M, Murakami S, Ohno S (2004) Sensitization of chemotherapy by anti-HER. Breast Cancer 11:105–115PubMedCrossRefGoogle Scholar
  30. 30.
    Aapro M, Johnson J (2005) Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3 receptor antagonists in the first 24 hours. Gerontology 51:287–296 doi: 10.1159/000086364 PubMedCrossRefGoogle Scholar
  31. 31.
    Aapro M, Extermann M, Repetto L (2000) Evaluation of the elderly with cancer. Ann Oncol 11:223–229 doi: 10.1023/A:1011156805700 PubMedCrossRefGoogle Scholar
  32. 32.
    Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ (2004) Saccharic acid 1.4-lactone protects against CPT-11 induced mucosa damage in rats. J Cancer Res Clin Oncol 130:388–394 doi: 10.1007/s00432-004-0557-8 PubMedCrossRefGoogle Scholar
  33. 33.
    Gibson R, Bowen J, Alvarez E, Finnie J, Keefe M (2007) Establishment of a single dose Irinotecan model of gastrointestinal mucositis. Chemotherapy 53:360–369 doi: 10.1159/000107458 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Noor Al-Dasooqi
    • 1
    • 2
    Email author
  • Joanne M. Bowen
    • 2
    • 3
  • Rachel J. Gibson
    • 2
    • 4
  • Thomas Sullivan
    • 5
  • Jude Lees
    • 6
  • Dorothy M. Keefe
    • 2
    • 3
    • 7
  1. 1.Department of PhysiologyUniversity of AdelaideAdelaideAustralia
  2. 2.Department of Medical OncologyRoyal Adelaide HospitalAdelaideAustralia
  3. 3.Department of MedicineUniversity of AdelaideAdelaideAustralia
  4. 4.Discipline of Anatomical SciencesUniversity of AdelaideAdelaideAustralia
  5. 5.Discipline of Public HealthUniversity of AdelaideAdelaideAustralia
  6. 6.RAH Cancer CentreRoyal Adelaide HospitalAdelaideAustralia
  7. 7.Cancer Council South AustraliaEastwoodAustralia

Personalised recommendations